Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2020 | Developing and understanding kinase inhibitors to treat CLL

Dimitar Efremov • 24 Sep 2020
ERIC 2020
Chronic Lymphocytic Leukemia Leukemia

Dimitar Efremov, MD, PhD, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, discusses how kinase inhibitors have improved for the treatment of chronic lymphocytic leukemia (CLL) by blocking survival signals. However, some treatments are less effective and these differences need to be explored so they can be considered when designing novel therapies. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.

More from Dimitar Efremov

2:02
The efficacy of plerixafor in the treatment of CLL
Dimitar Efremov • 10 Mar 2022
1:11
The role of macrophage signals and CXCR4 in the growth of CLL cells
Dimitar Efremov • 10 Mar 2022
1:25
An insight into the future treatment landscape of CLL
Dimitar Efremov • 10 Mar 2022
1:37
How BCR signaling influences cell proliferation in CLL
Dimitar Efremov • 10 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals